Stereotaxis, Inc. Stock Plummets to New 52-Week Low of $1.25

Stereotaxis, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.25 on July 28, 2026. This significant decline reflects a challenging year for the company, with its stock price plummeting by 64.25% over the past year, contrasting sharply with the S&P 500's performance of 16.26% during the same period. The company's market capitalization stands at USD 177 million, indicating its small size within the industry. Stereotaxis has not reported a price-to-earnings (P/E) ratio, as it is currently operating at a loss. Additionally, the company has a negative debt-to-equity ratio of -0.68 and a return on equity of -106.31%, highlighting financial difficulties. The price-to-book ratio is noted at 9.45, suggesting that the stock may be trading at a premium relative to its book value. As Stereotaxis navigates these financial metrics, the recent drop to its 52-week low underscores the ongoing volatility in its stock performance.